Explore stories from Atlantic Canada.
Stan Rogers Folk Festival 2024: 27 years of music and community | SaltWire #festival #music #ns - Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs in a late-stage study with details presented on Friday.Related stories
The study tested Scemblix in newly diagnosed patients with the blood cancer chronic myeloid leukemia against a class of drugs called tyrosine-kinase inhibitors , such as Novartis' own Glivec, that turned the disease from a death sentence into a treatable condition in which many patients had good, long-lasting responses.
During the trial, just 5% of Scemblix patients discontinued treatment due to adverse side effects, compared to a dropout rate of 10% of those being treated with any of the TKIs, which can cause fatigue, depression, disrupted sleep, diarrhea, and other side effects.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novartis leukemia drug more effective than older treatments in trialExplore stories from Atlantic Canada.
Read more »
Mexico's Sheinbaum: from activist to climate scientist to presidential frontrunnerExplore stories from Atlantic Canada.
Read more »
Xochitl Galvez, the maverick opposition candidate seeking Mexico's presidencyExplore stories from Atlantic Canada.
Read more »
Gilead's Trodelvy extends lung cancer survival by just 1.3 months in trialExplore stories from Atlantic Canada.
Read more »
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year dataExplore stories from Atlantic Canada.
Read more »
Finland, Estonia call for increased defence spending to ward off RussiaExplore stories from Atlantic Canada.
Read more »